{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:12:28Z","timestamp":1777043548645,"version":"3.51.4"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"North Carolina University Cancer Research Fund"},{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Geriatric Oncology Program","award":["T32-CA233419"],"award-info":[{"award-number":["T32-CA233419"]}]},{"name":"Cancer Control Education Program","award":["T32-CA057726"],"award-info":[{"award-number":["T32-CA057726"]}]},{"name":"Cancer Care Quality Training Program","award":["T32-CA116339"],"award-info":[{"award-number":["T32-CA116339"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The plasma cell disorders (PCDs), multiple myeloma (MM), and light-chain amyloidosis (AL) are disproportionately diseases of older adults, whose care may be complicated by frailty associated with advancing age. We sought to evaluate the prevalence of functional deficits and symptoms in a cohort of persons with PCDs and associations of demographic, disease-related, functional, and psychosocial measures with quality of life (QoL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Adults with PCDs were recruited into an observational registry in 2018-2020. Patients completed a functional assessment and European Organization for Research and Treatment of Cancer QoL questionnaire (QLQ-C30). Associations of covariates of interest with QoL were evaluated via univariate linear regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 121 adults, the mean age was 68.6. Diagnoses were 74% MM, 14% AL, 7% both MM and AL, and 5% other PCDs. The median time from diagnosis was 34.9 months. Median lines of therapy were 2, with 11% having received \u22654th-line therapy.<\/jats:p><jats:p>Patients with functional deficits had lower mean QoL scores: dependence in IADLs (66.3 vs. 79.9, P = .001) and recent falls (56.7 vs. 76.8, P = .001). Patients \u22646 months from diagnosis had lower QoL (66.7) than those \u22652 years from diagnosis (77.3, P = .03). However, patients on later lines of therapy (\u22654th-line) had lower QoL (62.2) than those on 1st-line treatment (76.0, P = .04).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Patients with physical impairments and more advanced PCDs had lower QoL than those without deficits or earlier in their disease course. Early identification of physical impairments may facilitate interventions that mitigate these deficits and thereby improve QoL for patients with PCDs.<\/jats:p><\/jats:sec>","DOI":"10.1093\/oncolo\/oyac079","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:14:21Z","timestamp":1649934861000},"page":"694-702","source":"Crossref","is-referenced-by-count":11,"title":["Physical Function, Psychosocial Status, and Symptom Burden Among Adults with Plasma Cell Disorders and Associations with Quality of Life"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6673-335X","authenticated-orcid":false,"given":"Christopher E","family":"Jensen","sequence":"first","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanah N","family":"Vohra","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten A","family":"Nyrop","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Division of Oncology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3526-3938","authenticated-orcid":false,"given":"Allison M","family":"Deal","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakira J","family":"Grant","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyman B","family":"Muss","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Division of Oncology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eben I","family":"Lichtman","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel M","family":"Rubinstein","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William A","family":"Wood","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J","family":"Mangieri","sequence":"additional","affiliation":[{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Jamison","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Division of Oncology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sascha A","family":"Tuchman","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill , Chapel Hill, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"2022080910385605600_CIT0001","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"2022080910385605600_CIT0002","author":"Kumar","year":"2021"},{"key":"2022080910385605600_CIT0003","author":"Kumar","year":"2021"},{"key":"2022080910385605600_CIT0004","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","article-title":"Multiple myeloma.","volume":"397","author":"Van De Donk","year":"2021","journal-title":"Lancet"},{"key":"2022080910385605600_CIT0005","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood.2020006913","article-title":"Management of AL amyloidosis in 2020.","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood."},{"key":"2022080910385605600_CIT0006","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/cncr.29119","article-title":"Health-related quality of life in older adult survivors of selected cancers: Data from the SEER-MHOS linkage.","volume":"121","author":"Kent","year":"2015","journal-title":"Cancer"},{"key":"2022080910385605600_CIT0007","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1186\/s12885-016-2410-2","article-title":"The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study.","volume":"16","author":"Ramsenthaler","year":"2016","journal-title":"BMC Cancer"},{"key":"2022080910385605600_CIT0008","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/0269216319833588","article-title":"Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: a prospective, multi-centre longitudinal study.","volume":"33","author":"Ramsenthaler","year":"2019","journal-title":"Palliative Med"},{"key":"2022080910385605600_CIT0009","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.clml.2018.08.019","article-title":"Health-related quality of life of patients with multiple myeloma treated in routine clinical practice in France.","volume":"19","author":"Despiegel","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022080910385605600_CIT0010","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1016\/j.clml.2020.10.002","article-title":"Real-world evaluation of health-related quality of life in patients with multiple myeloma from Germany.","volume":"21","author":"Engelhardt","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2022080910385605600_CIT0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s41669-019-0122-7","article-title":"Associations between health-related quality of life and self-reported emergency room department visits and inpatient hospitalizations: insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis.","volume":"3","author":"Mccausland","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"2022080910385605600_CIT0012","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma.","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"2022080910385605600_CIT0013","volume-title":"Cancer Stat Facts: Myeloma","author":"Surveillance, Epidemiology, and End Results (SEER) Program.","year":"2021"},{"key":"2022080910385605600_CIT0014","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.9206-17","article-title":"Nationwide survey of 741 patients with systemic amyloid light-chain amyloidosis in Japan.","volume":"57","author":"Shimazaki","year":"2018","journal-title":"Int Med"},{"key":"2022080910385605600_CIT0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mayocp.2018.08.041","article-title":"Incidence of AL amyloidosis in Olmsted county, Minnesota, 1990 through 2015.","volume":"94","author":"Kyle","year":"2019","journal-title":"Mayo Clin Proc."},{"key":"2022080910385605600_CIT0016","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1634\/theoncologist.2014-0247","article-title":"Geriatric assessment-identified deficits in older cancer patients with normal performance status.","volume":"20","author":"Jolly","year":"2015","journal-title":"Oncologist"},{"key":"2022080910385605600_CIT0017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jgo.2021.08.004","article-title":"Geriatric-assessment-identified functional deficits among adults with multiple myeloma with normal performance status.","volume":"13","author":"Jensen","year":"2022","journal-title":"J Geriatr Oncol"},{"key":"2022080910385605600_CIT0018","author":"Dotan"},{"key":"2022080910385605600_CIT0019","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1200\/JCO.2013.54.8347","article-title":"International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer.","volume":"32","author":"Wildiers","year":"2014","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0020","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology.","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0021","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","article-title":"Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: a Young International Society of Geriatric Oncology Review Paper.","volume":"12","author":"Grant","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"2022080910385605600_CIT0022","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer.","volume":"25","author":"Extermann","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0023","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma.","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0024","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0025","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1182\/blood-2015-05-647636","article-title":"Guidelines for determination of the number of prior lines of therapy in multiple myeloma.","volume":"126","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"2022080910385605600_CIT0026","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/cncr.21422","article-title":"Developing a cancer-specific geriatric assessment: a feasibility study.","volume":"104","author":"Hurria","year":"2005","journal-title":"Cancer"},{"key":"2022080910385605600_CIT0027","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1200\/JCO.2010.30.6985","article-title":"Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401.","volume":"29","author":"Hurria","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0028","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Compr Canc Netw"},{"key":"2022080910385605600_CIT0029","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0030","first-page":"191","article-title":"The clinical evaluation of chemotherapeutic agents in cancer.","volume-title":"Evaluation of Chemotherapeutic Agents in Cancer","author":"Karnofsky","year":"1949"},{"key":"2022080910385605600_CIT0031","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: reliability, validity, and guidelines.","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0032","doi-asserted-by":"crossref","first-page":"M139","DOI":"10.1093\/geronj\/46.4.M139","article-title":"The use of the Karnofsky Performance Scale in determining outcomes and risk in geriatric outpatients.","volume":"46","author":"Crooks","year":"1991","journal-title":"J Gerontol"},{"key":"2022080910385605600_CIT0033","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1532-5415.1991.tb01616.x","article-title":"The timed \u201cUp & Go\u201d: a test of basic functional mobility for frail elderly persons.","volume":"39","author":"Podsiadlo","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"2022080910385605600_CIT0034","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ptj\/80.9.896","article-title":"Predicting the probability of falls in community-dwelling older adults using the timed up and go test.","volume":"80","author":"Shumway-Cook","year":"2000","journal-title":"Phys Therapy"},{"key":"2022080910385605600_CIT0035","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1200\/JCO.1994.12.3.601","article-title":"Prospective evaluation of prognostic variables from patient-completed questionnaires.","volume":"12","author":"Loprinzi","year":"1994","journal-title":"J Clin Oncol"},{"key":"2022080910385605600_CIT0036","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/j.1532-5415.1990.tb03455.x","article-title":"Multiple stumbles: a risk factor for falls in community-dwelling elderly. A prospective study.","volume":"38","author":"Teno","year":"1990","journal-title":"J Am Geriatr Soc"},{"key":"2022080910385605600_CIT0037","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/geronj\/36.4.428","article-title":"The development, validity, and reliability of the OARS multidimensional functional assessment questionnaire.","volume":"36","author":"Fillenbaum","year":"1981","journal-title":"J Gerontol"},{"key":"2022080910385605600_CIT0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jclinepi.2019.10.003","article-title":"Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research.","volume":"118","author":"Giesinger","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2022080910385605600_CIT0039","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jgo.2018.08.009","article-title":"Mental status evaluation in older adults with cancer: Development of the Mental Health Index-13.","volume":"10","author":"Pergolotti","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2022080910385605600_CIT0040","volume-title":"EORTC QLQ-C30 Reference Values","author":"Scott","year":"2008"},{"key":"2022080910385605600_CIT0041","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry.","volume":"89","author":"Mols","year":"2012","journal-title":"Eur J Haematol"},{"key":"2022080910385605600_CIT0042","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life.","volume":"46","author":"Boland","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"2022080910385605600_CIT0043","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States.","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"},{"key":"2022080910385605600_CIT0044","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s11136-019-02392-6","article-title":"How are patient-reported outcomes and symptoms being measured in adults with relapsed\/refractory multiple myeloma? A systematic review.","volume":"29","author":"Leblanc","year":"2020","journal-title":"Qual Life Res"},{"key":"2022080910385605600_CIT0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice.","volume":"175","author":"Yong","year":"2016","journal-title":"Br J Haematol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/694\/45293611\/oyac079.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/8\/694\/45293611\/oyac079.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T23:30:45Z","timestamp":1675294245000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/8\/694\/6577295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":45,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,5,3]]},"published-print":{"date-parts":[[2022,8,5]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac079","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,8,1]]},"published":{"date-parts":[[2022,5,3]]}}}